Description
Indication & Scope
PaiDaKang® Visepegenatide Injection provides glycemic control in adult patients diagnosed with type 2 diabetes mellitus.
- Mechanism: Long-acting GLP-1 receptor agonist. It activates GLP-1 receptors on pancreatic beta cells to promote glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying and reduce food intake, lowering fasting and postprandial blood glucose.
- Drug class: Glucagon-like peptide-1 (GLP-1) receptor agonist / Injectable hypoglycemic peptide drug.
- Clinical use: Single-agent glycemic management for type 2 diabetes adults; can be combined with metformin for enhanced blood sugar reduction and mild weight control.
| Generic Name | Visepegenatide Injection |
| Brand Name | PaiDaKang |
| Ingredient | Visepegenatide |
| Dosage Form | Injection |
| Package | 0.3ml: 0.97mg*1 syringe/box |
| Conditions Treated | Type 2 diabetes mellitus in adult patients |
| Taboos | Patients with personal or family history of medullary thyroid carcinoma; multiple endocrine neoplasia syndrome type 2; severe hypersensitivity to GLP-1 peptides or injection excipients; pregnant and breastfeeding women |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Unopened injection pens: store refrigerated at 2°C to 8°C, avoid freezing. After first use: store below 25°C within 4 weeks, away from direct sunlight |
| Manufacturer | Peptide Biopharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20250066 |
| Approval Date | Nov 12, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Initial starting dose: 0.3 mg once weekly subcutaneously; titrate up to maintenance 0.97 mg weekly based on individual glycemic response.
Time: Inject subcutaneously once every 7 days, can be administered at any time of day independent of meals.
Instructions for use: Administer subcutaneous injection into abdomen, thigh or upper arm; rotate injection sites weekly to avoid local reaction; adjust dose gradually to minimize gastrointestinal discomfort.
Interaction: Concurrent insulin or sulfonylurea hypoglycemics increase hypoglycemia risk; calcium/magnesium oral supplements delay peptide absorption, separate administration by 2 hours.
Side effects:
1. Common: mild nausea, diarrhea, vomiting, injection site redness, fatigue.
2. Rare severe risks: acute pancreatitis, gallbladder stone formation, severe hypoglycemia when combined with insulin.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What patient population is Visepegenatide Injection indicated for?
Adult patients with type 2 diabetes mellitus for blood glucose management.
How frequently do patients receive Visepegenatide Injection?
Subcutaneous injection once per week.
What two patient groups are strictly contraindicated to use Visepegenatide Injection?
Those with thyroid medullary carcinoma history and patients with adult type 2 syndrome.
What drug interaction with Visepegenatide Injection increases the risk of hypoglycemia?
Combined use with insulin or sulfonylurea hypoglycemic medicines.
PaiDaKang® | Visepegenatide Injection | Type 2 Diabetes | DengYueRX
INN: Visepegenatide Injection
Indications: Type 2 diabetes
Dosage Form: Injection
Strength: 0.3ml: 0.97mg/syringe
